Recursion Pharmaceuticals Ownership
| RXRX Stock | USD 6.53 0.26 3.83% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 282.6 M | Current Value 336 M | Avarage Shares Outstanding 188.2 M | Quarterly Volatility 57.2 M |
Recursion |
Recursion Stock Ownership Analysis
About 77.0% of the company shares are owned by institutional investors. The book value of Recursion Pharmaceuticals was at this time reported as 2.61. The company recorded a loss per share of 1.69. Recursion Pharmaceuticals had not issued any dividends in recent years. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Recursion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 400 people. To find out more about Recursion Pharmaceuticals contact Christopher Gibson at 385 269 0203 or learn more at https://www.recursion.com.Besides selling stocks to institutional investors, Recursion Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Recursion Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Recursion Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Recursion Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Recursion Pharmaceuticals Insider Trades History
Roughly 4.0% of Recursion Pharmaceuticals are currently held by insiders. Unlike Recursion Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Recursion Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Recursion Pharmaceuticals' insider trades
Recursion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Recursion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Recursion Pharmaceuticals backward and forwards among themselves. Recursion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Recursion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ra Capital Management, Llc | 2024-12-31 | 7.7 M | Nvidia Corp | 2024-12-31 | 7.7 M | Fmr Inc | 2024-12-31 | 7.1 M | Geode Capital Management, Llc | 2024-12-31 | 6.1 M | Data Collective Iv Gp, Llc | 2024-12-31 | 5.9 M | Dcvc Opportunity Fund Ii Gp, Llc | 2024-12-31 | 4 M | Exor Investments (uk) Llp | 2024-12-31 | 3.7 M | Norges Bank | 2024-12-31 | 3.5 M | Ubs Group Ag | 2024-12-31 | 3 M | Vanguard Group Inc | 2024-12-31 | 34 M | Ark Investment Management Llc | 2024-12-31 | 32.3 M |
Recursion Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Recursion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Recursion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Recursion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Recursion Pharmaceuticals Outstanding Bonds
Recursion Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Recursion Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Recursion bonds can be classified according to their maturity, which is the date when Recursion Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| RKTLN 3 26 JUN 27 Corp BondUS75625QAE98 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Recursion Pharmaceuticals Corporate Filings
F3 | 19th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.